UBS Group AG Lowers Stock Holdings in GH Research PLC $GHRS

UBS Group AG reduced its holdings in GH Research PLC (NASDAQ:GHRS) by 29.0% during the 4th quarter, Holdings Channel reports. The firm owned 363,381 shares of the company’s stock after selling 148,083 shares during the quarter. UBS Group AG’s holdings in GH Research were worth $4,615,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GHRS. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research in the fourth quarter valued at approximately $38,000. Osaic Holdings Inc. grew its holdings in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the period. JPMorgan Chase & Co. acquired a new stake in GH Research in the second quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in GH Research in the fourth quarter valued at approximately $128,000. Finally, BNP Paribas Financial Markets grew its holdings in GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the period. 56.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GHRS has been the topic of several research analyst reports. Citizens Jmp dropped their price objective on GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a report on Friday, May 15th. Cantor Fitzgerald boosted their target price on shares of GH Research from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Citigroup restated an “outperform” rating on shares of GH Research in a research report on Friday, May 15th. HC Wainwright reduced their price target on shares of GH Research from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Royal Bank Of Canada upped their price target on shares of GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.38.

GH Research Stock Up 1.6%

GHRS opened at $22.12 on Friday. GH Research PLC has a twelve month low of $10.66 and a twelve month high of $24.66. The company has a 50-day moving average price of $17.78 and a 200 day moving average price of $15.82. The company has a market cap of $1.52 billion, a PE ratio of -24.04 and a beta of 1.27.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). As a group, sell-side analysts expect that GH Research PLC will post -1.46 earnings per share for the current year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.